Skip to main content

Jay Kranzler, M.D., Ph.D.

Equibles does not estimate personal net worth.

Get an email with a short summary when Avenue Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.

Get ATXI alerts

About Jay Kranzler, M.D., Ph.D.

Jay Kranzler, M.D., Ph.D. is recorded as Board Member at Avenue Therapeutics, Inc. (ATXI) since June 24, 2024 and Chairman at Avenue Therapeutics, Inc. (ATXI) since March 7, 2023. Avenue Therapeutics, Inc. reported in an 8-K filed June 26, 2024 that Jay Kranzler, M.D., Ph.D. was appointed Director, effective June 24, 2024. Avenue Therapeutics, Inc. reported in an 8-K filed March 8, 2023 that Jay Kranzler, M.D., Ph.D. was appointed Chairman of the Board, effective March 7, 2023. Avenue Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Avenue Therapeutics, Inc. includes Alexandra MacLean (CEO and Board Member), Alexandra MacLean, M.D. (CEO and Board Member), David Jin (CFO) and 7 others.

“the election of six directors to hold office until the 2025 annual meeting of stockholders”
Avenue Therapeutics, Inc. Form 8-K, filed June 26, 2024 · Read the filing
“Also on March 7, 2023, the Board appointed Jay Kranzler, M.D., Ph.D. to serve as Chairman of the Board, effective immediately, in place of Lindsay A. Rosenwald, M.D.”
Avenue Therapeutics, Inc. Form 8-K, filed March 8, 2023 · Read the filing

Affiliation history

Company network

Leadership on record at Avenue Therapeutics, Inc.

Recent activity